

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

209607Orig1s000

MULTI-DISCIPLINE REVIEW

Summary Review

Office Director

Cross Discipline Team Leader Review

Clinical Review

Non-Clinical Review

Statistical Review

Clinical Pharmacology Review

NDA/BLA Multi-Disciplinary Review and Evaluation

Application Type	NDA
Application Number	209607
Priority or Standard	Priority
Submit Date	10-31-2017
Received Date	10-31-2017
PDUFA Goal Date	7-30-2018
Division/Office	DOP2/OHOP
Review Completion Date	7-24-2018
Established Name	¹³¹ I Iobenguane
(Proposed) Trade Name	AZEDRA
Pharmacologic Class	Radiopharmaceutical
Code name	
Applicant	Progenics Pharmaceuticals Inc.
Formulation	Solution
Dosing Regimen	Dosimetric dose: 5 – 6 mCi (0.1 mCi/kg for patients ≤ 50 kg) Therapeutic dose: 500 mCi (8 mCi/kg for patients ≤ 62.5 kg) every 12 weeks for two doses
Applicant Proposed Indication	Treatment of patients age ^(b) ₍₄₎ years and older with Iobenguane avid malignant and/or recurrent pheochromocytoma or paraganglioma
Recommendation on Regulatory Action	Approval
Recommended Indication	Treatment of patients age 12 years and older with Iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy

Table of Contents

Reviewers of Multi-Disciplinary Review and Evaluation.....	9
Additional Reviewers of Application	9
Glossary	10
1 Executive Summary	12
1.1 Product Introduction	12
1.2 Conclusions on the Substantial Evidence of Effectiveness	14
1.3 Benefit-Risk.....	16
1.4 Patient Experience Data	22
2 Therapeutic Context	24
2.1 Analysis of Condition	24
2.2 Analysis of Current Treatment Options	25
3 Regulatory Background	27
3.1 U.S. Regulatory Actions and Marketing History.....	27
3.2 Summary of Presubmission/Submission Regulatory Activity	27
4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety	31
4.1 Office of Scientific Investigations (OSI).....	31
4.2 Product Quality	31
4.3 Clinical Microbiology	31
4.4 Devices and Companion Diagnostic Issues	31
4.5 Division of Medical Imaging Products.....	32
5 Nonclinical Pharmacology/Toxicology	33
5.1 Executive Summary	33
5.2 Referenced NDAs, BLAs, DMFs	35
5.3 Pharmacology	35
5.4 ADME/PK	44
5.5 Toxicology	46
5.5.1 General Toxicology	46
5.5.2 Genetic Toxicology.....	48

NDA/BLA Multi-Disciplinary Review and Evaluation {NDA 209607}
{AZEDRA, ¹³¹I-MIBG}

5.5.3 Carcinogenicity	49
5.5.4 Reproductive and Developmental Toxicology	49
5.5.5 Other Toxicology Studies	50
6 Clinical Pharmacology	51
6.1 Executive Summary	51
6.2 Recommendations	51
6.3 Postmarketing Requirements and Commitments	52
6.4 Summary of Clinical Pharmacology Assessment	52
6.5 Pharmacology and Clinical Pharmacokinetics	52
6.6 General Dosing and Therapeutic Individualization	53
6.6.1 General Dosing	53
6.6.2 Therapeutic Individualization	53
6.6.3 Outstanding Issues	54
6.6.4 Summary of Labeling Recommendations	55
6.7 Comprehensive Clinical Pharmacology Review	55
6.7.1 General Pharmacology and Pharmacokinetic Characteristics	55
6.7.2 Clinical Pharmacology Questions	57
[Source: NDA 209607/SDN 2 – FDA’s IRT-QTc Review, PP 2]	63
7 Sources of Clinical Data and Review Strategy	71
7.1 Table of Clinical Studies	71
7.2 Review Strategy	73
8 Statistical and Clinical and Evaluation	74
8.1 Review of Relevant Individual Trials Used to Support Efficacy	74
8.1.1 MIP-IB12B: A Phase II Study Evaluating the Efficacy and Safety of ¹³¹ I-MIBG in Patients with Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma	74
8.1.2 MIP-IB12B Study Results	81
8.1.3 Study MIP-IB12: A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety and Efficacy of Ultratrace Iobenguane I 131 in Patients with Malignant Pheochromocytoma/ Paraganglioma	97
8.1.4 Assessment of Efficacy Across Trials	100
8.1.5 Integrated Assessment of Effectiveness	101
8.2 Review of Safety	101

NDA/BLA Multi-Disciplinary Review and Evaluation {NDA 209607}
{AZEDRA, ¹³¹I-MIBG}

8.2.1 Safety Review Approach	102
8.2.2 Review of the Safety Database	103
8.2.3 Adequacy of Applicant’s Clinical Safety Assessments.....	104
8.2.4 Safety Results.....	106
8.2.5 Analysis of Submission-Specific Safety Issues.....	127
8.2.6 Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability	129
8.2.7 Safety Analyses by Demographic Subgroups.....	130
8.2.8 Specific Safety Studies/Clinical Trials.....	131
8.2.9 Additional Safety Explorations.....	131
8.2.10 Safety in the Postmarket Setting	133
8.2.11 Integrated Assessment of Safety	133
10 SUMMARY AND CONCLUSIONS	135
10.1 Statistical Issues.....	135
10.2 Conclusions and Recommendations.....	135
11 Advisory Committee Meeting and Other External Consultations	137
12 Pediatrics	138
13 Labeling Recommendations	138
13.1 Prescription Drug Labeling.....	138
14 Risk Evaluation and Mitigation Strategies (REMS).....	140
15 Postmarketing Requirements and Commitments	141
16 Division Director (DHOT)	142
17 Division Director (OCP)	143
18 Division Director (OB)	144
19 Division Director (Clinical)	145
21 Appendices	150
21.1 References	150
21.2 Financial Disclosure	153
21.3 Nonclinical Pharmacology/Toxicology.....	154

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.